Improvement of prefrontal brain function in endogenous psychoses under atypical antipsychotic treatment

Neuropsychopharmacology

Volumn 32, Issue 8, 2007, Pages 1669-1677

  Ehlis, Ann Christine ^a   Herrmann, Martin J ^a   Pauli, Paul ^a   Stoeber, Gerald ^a   Pfuhlmann, Bruno ^a   Fallgatter, Andreas J ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Anterior cingulate cortex (ACC); Antipsychotics; Event related potentials (ERP); Prefrontal cortex; Response inhibition; Schizophrenia

Indexed keywords

AMISULPRIDE; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; BIPERIDEN; CARBAMAZEPINE; CHLORPROMAZINE; CHLORPROTHIXENE; CLOZAPINE; FLUPENTIXOL; LITHIUM; MELPERONE; NEUROLEPTIC AGENT; OLANZAPINE; PERAZINE; PERPHENAZINE; PIPAMPERONE; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE;

ADULT; ARTICLE; BRAIN FUNCTION; CLINICAL ARTICLE; CORRELATION ANALYSIS; ELECTROPHYSIOLOGY; ENDOGENOUS PSYCHOSIS; FEMALE; FOLLOW UP; FRONTAL LOBE; HUMAN; MALE; MEDICAL PARAMETERS; NEUROPHYSIOLOGY; NEUROPSYCHOLOGICAL TEST; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHIATRIC TREATMENT; SCHIZOPHRENIA;

ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CHI-SQUARE DISTRIBUTION; CHOICE BEHAVIOR; ELECTROENCEPHALOGRAPHY; EVOKED POTENTIALS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; PREFRONTAL CORTEX; PSYCHIATRIC STATUS RATING SCALES; PSYCHOTIC DISORDERS; REACTION TIME; STATISTICS;

EID: 34447506203     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.npp.1301293     Document Type: Article

References (73)

1. Andreasen NC, Rezai K, Alliger R, Swayze VW, Flaum M, Kirchner P et al (1992). Hypofrontality in neuroleptic-naive patients with Xenon 133 single-photon emission computed tomography and the tower of London. Arch Gen Psychiatry 49: 943-958.
2. Barch DM, Braver TS, Akbudak E, Conturo T, Ollinger J, Snyder A (2001). Anterior cingulate cortex and response conflict: effects of response modality and processing domain. Cereb Cortex 11: 837-848.
3. Bartlett EJ, Brodie JD, Simkowitz P, Dewey SL, Rusinek H, Wolf AP et al (1994). Effects of haloperidol challenge on regional cerebral glucose utilization in normal human subjects. Am J Psychiatry 151: 681-686.
4. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B et al (2002). Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 1018-1028.
5. Borison RL (1996). The role of cognition in the risk-benefit and safety analysis of antipsychotic medication. Acta Psychiatr Scand Suppl 389: 5-11.
6. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Henn FA (2001). Favorable effect on neuronal viability in the anterior cingulate gyrus due to long-term treatment with atypical antipsychotics: an MRSI study. Pharmacopsychiatry 34: 251-253.
7. Braus DF, Ende G, Weber-Fahr W, Demirakca T, Tost H, Henn FA (2002). Functioning and neuronal viability of the anterior cingulate neurons following antipsychotic treatment: MR-spectroscopic imaging in chronic schizophrenia. Eur Neuropsychopharmacol 12: 145-152.
8. Carter CS, MacDonald AW, Ross LL, Stenger VA (2001). Anterior cingulate cortex activity and impaired self-monitoring of performance in patients with schizophrenia: an event-related fMRI study. Am J Psychiatry 158: 1423-1428.
9. 2O PET study during single-trial Stroop task performance. Am J Psychiatry 154: 1670-1675.
10. Carter CS, Perlstein W, Ganguli R, Brar J, Mintun M, Cohen JD (1998). Functional hypofrontality and working memory dysfunction in schizophrenia. Am J Psychiatry 155: 1285-1287.
11. Cuenod CA, Bookheimer SY, Hertz-Pannier L, Zeffiro TA, Theodore WH, Le Bihan D (1995). Functional MRI during word generation, using conventional equipment: a potential tool for language localization in the clinical environment. Neurology 45: 1821-1827.
12. Cuesta MJ, Peralta V, Zarzuela A (2001). Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res 48: 17-28.
13. de Zubicaray GI, Zelaya FO, Andrew C, Williams SC, Bullmore ET (2000). Cerebral regions associated with verbal response initiation, suppression and strategy use. Neuropsychologia 38: 1292-1304.
14. 1A receptors in prefrontal cortex in the modulation of dopaminergic activity: role in atypical antipsychotic action. J Neurosci 25: 10831-10843.
15. Dickins DW, Singh KD, Roberts N, Burns P, Downes JJ, Jimmieson P et al (2001). An fMRI study of stimulus equivalence. Neuroreport 12: 405-411.
16. Dolan R, Frith CD, Friston KJ, Frackowiak RSJ, Grasby PM (1995). Dopaminergic modulation of impared cognitive activation in the ACG in schizophrenia. Nature 378: 180-183.
17. Ende G, Braus DF, Walter S, Weber-Fahr W, Soher B, Maudsley AA et al (2000). Effects of age, medication, and illness duration on the N-acetyl-aspartate signal of the anterior cingulate region in schizophrenia. Schizophr Res 41: 389-395.
18. Fallgatter AJ, Aranda DR, Bartsch AJ, Herrmann MJ (2002a). Long-term reliability of electrophysiologic response control parameters. J Clin Neurophysiol 19: 61-66.
19. Fallgatter AJ, Bartsch AJ, Eisenack S, Neuhauser B, Aranda D, Herrmann MJ (2001). Reliability of electrophysiological parameters assessing human motor control. Clin Neurophysiol 112: 198-204.
20. Fallgatter AJ, Bartsch AJ, Herrmann MJ (2002b). Electrophysiological measurements of anterior cingulate function. J Neural Transm 109: 977-988.
21. Fallgatter AJ, Bartsch AJ, Zielasek J, Herrmann MJ (2003). Brainelectrical dysfunction of the anterior cingulate in schizophrenic patients. Psychiatry Res 124: 37-48.
22. Fallgatter AJ, Brandeis D, Strik WK (1997). A robust assessment of the NoGo-anteriorisation of P300 microstates in a cued continuous performance test. Brain Topogr 9: 295-302.
23. Fallgatter AJ, Eisenack SS, Neuhauser B, Aranda D, Scheuerpflug P, Herrmann MJ (2000). Stability of late event-related potentials: topographical descriptors of motor control compared with the P300 amplitude. Brain Topogr 12: 255-261.
24. Fallgatter AJ, Mueller TJ (2001). Electrophysiological signs of reduced prefrontal response control in schizophrenic patients. Psychiatry Res 107: 19-28.
25. Fallgatter AJ, Müller TJ, Strik WK (1999). Age-related changes in brain electrical correlates of response control. Clin Neurophysiol 110: 833-838.
26. Fallgatter AJ, Strik WK (1999). The NoGo-anteriorisation as a neurophysiological standard-index for cognitive response control. Int J Psychophysiol 32: 115-120.
27. Ford JM, Gray M, Whitfield SL, Turken AU, Glover G, Faustman WO et al (2004). Acquiring and inhibiting prepotent responses in schizophrenia: event-related brain potentials and functional magnetic resonance imaging. Arch Gen Psychiatry 61: 119-129.
28. Gaillard WD, Hertz-Pannier L, Mott SH, Barnett AS, LeBihan D, Theodore WH (2000). Functional anatomy of cognitive development: fMRI of verbal fluency in children and adults. Neurology 54: 180-185.
29. Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H (1996). Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. Eur Neuropsychopharmacol 6(Suppl 2): 13-20.
30. Glahn DC, Ragland JD, Abramoff A, Barrett J, Laird AR, Bearden CE et al (2005). Beyond hypofrontality: a quantitative meta-analysis of functional neuroimaging studies of working memory in schizophrenia. Hum Brain Mapp 25: 60-69.
31. Goldberg TE, Hyde TM, Kleinman JE, Weinberger DR (1993). Course of schizophrenia: neuropsychological evidence for a static encephalopathy. Schizophr Bull 19: 797-804.
32. Gratton G, Coles MGH (1989). Generalization and evaluation of eye-movement correction procedures. J Psychophysiol 3: 1-50.
33. Green MF, Marshall Jr BD, Wirshing WC, Ames D, Marder SR, McGurk S et al (1997). Does risperidone improve verbal working memory in treatment-resistant schizophrenia? Am J Psychiatry 154: 799-804.
34. Gur RE, Kohler C, Ragland JD, Siegel SJ, Bilker WB, Loughead J et al (2003). Neurocognitive performance and clinical changes in olanzapine-treated patients with schizophrenia. Neuropsychopharmacology 28: 2029-2036.
35. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23: 56-62.
36. Haznedar MM, Buchsbaum MS, Luu C, Hazlett EA, Siegel Jr BV, Lohr J et al (1997). Decreased anterior cingulate gyrus metabolic rate in schizophrenia. Am J Psychiatry 154: 682-684.
37. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T (1999). Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 96: 13432-13437.
38. Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P et al (2006). Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS-drugs 20: 389-409.
39. Ichikawa J, Dai J, O'Laughlin IA, Fowler WL, Meltzer HY (2002). Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology 26: 325-339.
40. Ichikawa J, Meltzer HY (1999). Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur Arch Psychiatry Clin Neurosci 249(Suppl 4): 90-98.
41. Ingvar DH, Franzen G (1974). Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatr Scand 50: 425-462.
42. Kay SR, Fiszbein A, Opler LA (1987). The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261-277.
43. Laurens KR, Ngan ET, Bates AT, Kiehl KA, Liddle PF (2003). Rostral anterior cingulate cortex dysfunction during error processing in schizophrenia. Brain 126: 610-622.
44. Laux G, Dietmaier O, Koenig W (2000). Pharmakopsychiatrie, 3rd edn. Urban & Fischer, Muenchen. p 237.
45. Lee MA, Thompson PA, Meltzer HY (1994). Effects of clozapine on cognitive function in schizophrenia. J Clin Psychiatry 55(Suppl B): 82-87.
46. Lehmann D (1987). Principles of spatial analysis. In: Gevins A, Remond A (eds). Handbook of Electroencephalography and Clinical Neurophysiology, Vol. 1: Methods of Analysis of Brain Electrical and Magnetic Signals. Elsevier: Amsterdam. pp 309-354.
47. Lewander T (1994). Neuroleptics and the neuroleptic-induced deficit syndrome. Acta Psychiatr Scand Suppl 380: 8-13.
48. Li XM, Perry KW, Wong DT, Bymaster FP (1998). Olanzapine increases in vivo dopamine and norepinephrine release in reat prefrontal cortex, nucleus accumbens and striatum. Psychopharmacol 136: 153-161.
49. MacDonald III AW, Carter CS (2003). Event-related FMRI study of context processing in dorsolateral prefrontal cortex of patients with schizophrenia. J Abnorm Psychol 112: 689-697.
50. Madsen AL, Keiding N, Karle A, Esbjerg S, Hemmingsen R (1998). Neuroleptics in progressive structural brain abnormalities in psychiatric illness. Lancet 352: 784-785.
51. Matthews SC, Paulus MP, Simmons AN, Nelesen RA, Dimsdale JE (2004). Functional subdivisions within anterior cingulate cortex and their relationship to autonomic nervous system function. NeuroImage 22: 1151-1156.
52. Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD (2001). Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia. Biol Psychiatry 49: 704-715.
53. Overall JE, Gorham DR (1962). The brief psychiatric rating scale. Psychol Rev 10: 799-812.
54. Pascual-Marqui RD, Michel CM, Lehmann D (1994). Low resolution electromagnetic tomography, a new method for localizing electrical activity in the brain. Int J Psychophysiol 18: 49-65.
55. Pehek EA, Yamamoto BK (1994). Differential effects of locally administered clozapine and haloperidol on dopamine efflux in the rat prefrontal cortex and caudate-putamen. J Neurochem 63: 2118-2124.
56. Purdon SE, Jones BDW, Stip E, Labelle A, Addington D, David SR et al (2000). Neuropsychological change in early pahse schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. Arch Gen Psychiatry 57: 249-258.
57. Purdon SE, Malla A, Labelle A, Lit W (2001). Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol. J Psychiatry Neurosci 26: 137-149.
58. Riley EM, McGovern D, Mockler D, Doku VC, O'Ceallaigh S, Fannon DG et al (2000). Neuropsychological functioning in first-episode psychosis - evidence of specific deficits. Schizophr Res 43: 47-55.
59. Rodriguez-Sanchez JM, Crespo-Facorro B, Iglesias RP, Bosch CG, Alvarez M, Llorca J et al (2005). Prefrontal cognitive functions in stabilized first-episode patients with schizophrenia spectrum disorders: a dissociation between dorsolateral and orbitofrontal functioning. Schizophr Res 77: 279-288.
60. Rosvold HE, Mirsky A, Sarason I, Bransome Jr ED, Beck LH (1956). A continuous performance test of brain damage. J Consult Psychol 20: 343-350.
61. Rubia K, Russell T, Bullmore ET, Soni W, Brammer MJ, Simmons A et al (2001). An fMRI study of reduced left prefrontal activation in schizophrenia during normal inhibitory function. Schizophr Res 52: 47-55.
62. Ruff CC, Woodward TS, Laurens KR, Liddle PF (2001). The role of the anterior cingulate cortex in conflict processing: evidence from reverse stroop interference. NeuroImage 14: 1150-1158.
63. Siegel Jr BV, Buchsbaum MS, Bunney Jr WE, Gottschalk LA, Haier RJ, Lohr JB et al (1993). Cortical-striatal-thalamic circuits and brain glucose metabolic activity in 70 unmedicated male schizophrenic patients. Am J Psychiatry 150: 1325-1336.
64. Stip E, Lussier I (1996). Effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 41(Suppl 8): 35-40.
65. Strik WK, Fallgatter AJ, Brandeis D, Pascual-Marqui R (1998). Three dimensional tomography of event-related potentials during response inhibition: evidence for phasic frontal lobe activation. Electroencephalogr Clin Neurophysiol 108: 406-413.
66. Stroop JR (1935). Studies of interference in serial verbal reactions. J Exp Psychol 18: 643-662.
67. Swick D, Jovanovic J (2002). Anterior cingulate cortex and the Stroop task: neuropsychological evidence for topographic specificity. Neuropsychologia 40: 1240-1253.
68. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN et al (1992). Limbic system abnormalities identified in schizophrenia with fluorodeoxyglucose and neocortical alterations with the deficit syndrome. Arch Gen Psychiatry 49: 522-530.
69. Velligan DI, Newcomer J, Pultz J, Csernansky J, Hoff AL, Mahurin R et al (2002). Does cognitive function improve with quetiapine in comparison to haloperidol? Schizophr Res 53: 239-248.
70. Volz H, Gaser C, Hager F, Rzanny R, Ponisch J, Mentzel H et al (1999). Decreased frontal activation in schizophrenics during stimulation with the continuous performance test - a functional magnetic resonance imaging study. Eur Psychiatry 14: 17-24.
71. Wittchen HU, Zaudig M, Fydrich T (1997). Strukturiertes Klinisches Interview für DSM-IV (SKID I und II). Deutsche Bearbeitung. Hogrefe: Göttingen.
72. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663-667.
73. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8: 457-472.